For example, gene amplifications of EGFR can promote EGFR-dependent signaling and qualify this receptor tyrosine kinase as a therapeutic target in HNSCC treatment, although predominantly for palliative treatment [4,23]. The gene discussed is NTRK1; the disease is head and neck squamous cell carcinoma.